Novartis
-
BeiGene, Novartis Drug Alliance Ends; It’s Their Second Terminated Deal This Year
BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.
-
HHS Will Likely Face More Lawsuits Against Drug Price Negotiation Now That It Has Named the First 10 Meds Included In the Plan
Novartis became the seventh drugmaker to legally challenge the White House’s Medicare drug pricing negotiation program. The company filed its lawsuit three days after HHS announced the first 10 drugs that were selected for the program — its heart failure medication Entresto was one on the list. HHS can expect to face more lawsuits from the manufacturers of the 10 drugs it named last week, experts have warned.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Novartis Pays Ionis $60M to Expand Alliance on a Hot Target for Cardio Drugs
Novartis and Ionis Pharmaceuticals, already partners in cardiovascular disease R&D, are expanding their alliance to see if they can develop a next-generation therapy offering efficacy and dosing advantages. But competitors are already in the mix with programs addressing the same cardiovascular disease target.
-
Here’s Why Novartis Is Paying $500M to Acquire a Preclinical RNA Startup
Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.
-
With End of Alliance, Novartis Walks Away From Once Hot Cancer Target
Novartis and BeiGene ended their partnership on a cancer immunotherapy for a target called TIGIT. Though BeiGene describes the termination as mutual, it comes before Novartis would need to pump more money into the alliance even as questions linger about TIGIT as a cancer target.
-
Bausch + Lomb Broadens Eye Products Lineup Via $1.75B Deal With Novartis
Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition. The deal with Novartis also includes two experimental products, one for eye pain and the other a medical device for delivering medicines to the eye.
-
Novartis Lines Up $3.2B Deal for Kidney Disease Drugs, But FTC Questions Loom
Novartis is acquiring Chinook Therapeutics in a $3.2 billion deal that brings two late-stage drug candidates for a rare kidney disorder. The Novartis drug pipeline already has a molecule in late-stage development for the same kidney disease, which could raise questions from antitrust regulators.
-
Novartis Puts Up $50M to Steer Bicycle Therapeutics’ Tech Into New Cancer Meds
Novartis is partnering with Bicycle Therapeutics to see if the biotech’s technology can be used to develop better, more targeted radiopharmaceuticals. The deal covers two targets that were not disclosed.
-
As Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing
Cell therapy offers a treatment option for some advanced blood cancers, but the manufacturing process is lengthy and complex. The biopharmaceutical industry is working on various technologies that could make manufacturing faster and more efficient, or perhaps supplant the current process altogether.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Novartis Tops AstraZeneca With Blood Drug Data at ASH; FDA Is Next Stop
Nearly all patients treated with the Novartis drug iptacopan achieved the hemoglobin goals of a pivotal study compared to zero patients who received the AstraZeneca drugs that are the standard of care in a rare blood disorder. The results were presented Tuesday during the annual meeting of the American Society of Hematology.
-
MedCity Influencers, BioPharma
Gene therapy is saving lives; There are still key challenges to realize its full potential
Gene therapy can offer hope to patients with previously untreatable diseases, but there’s more work to be done to improve both the safety and efficacy of this therapeutic modality.
-
European approval of Novartis cancer drug puts a new STAMP on leukemia
Novartis drug Scemblix is the first in a new class of drugs known as STAMP inhibitors. European Commission approval of the small molecule provides a new treatment option for chronic myeloid leukemia that is resistant to earlier treatments, as well as those cases in which patients cannot tolerate the other therapies for this blood cancer.
-
Novartis warns of two patient deaths after dosing with gene therapy Zolgensma
The two deaths reported following treatment with Novartis’s Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy. Liver complications are a known side effect risk of Zolgensma and other genetic medicines that are delivered by engineered viruses.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.
-
FDA delay means BeiGene, Novartis must wait longer for cancer drug decision
The FDA has deferred a regulatory decision on an esophageal cancer drug from partners BeiGene and Novartis, citing the need to complete inspections of the China-based facilities where the drug is made. The agency said Covid-19 travel restrictions have prevented it from conducting those inspections.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
